News Articles for Dimerix

This week's Bulls N' Bears Runner of the Week is … Sparc Technologies. The company is developing new-age hydrogen technology using sunlight to split water without the use of an electrolyser. Argent Biopharma raised funds at a significant premium to its last closing price while Australian Mines boosted its scandium resource and Dimerix revealed a tie-in with a Japanese pharmaceutical firm to treat kidney disease.

There's a Perth connection to a deal struck by pharmaceutical company Dimerix with UK-based Advanz Pharma worth up to $230 million.

Three new local funds proposing to focus on early-stage investment are raising expectations.

Perth-founded biopharmaceutical business Dimerix has launched phase three drug trials for patients with COVID-19 and kidney diseases.

Peter Meurs and Perth-based Merchant Group have invested $9.5 million in biopharmaceutical company Dimerix, as part of a broader capital raising to fast-track clinical studies.

It has taken over 15 years, but Perth-based medical technology company Proteomics International is now launching a commercial product targeted at the US.

Experienced biotech and pharmaceuticals professional, Dr Nina Webster, has been appointed chief executive and managing director of Dimerix.

Black Mountain Resources Limited is pleased to update shareholders on the following restructure initiatives that have been agreed to by the Company and its major lender, Richmond Partners Masters L

Nicholas Clark has retired as executive director, strategy at Alexium International Group to focus on his young family in the US following the unexpected loss of his wife last year.

40under40: Kevin Pfleger is on a mission to turn WA medical research into solutions for chronic disease.

Fortescue Metals Group is home to two of Western Australia's wealthiest company directors, or so it was believed until a surprise disclosure last month.

Local biotech firm Sun Biomedical has announced plans to buy Melbourne-based Dimerix Bioscience in exchange for a share package worth about $8.3 million.

FEATURE: The June quarter presented a broad range of transactions for corporate players, however a noticeable lack of direction remains.

FEATURE: The state's biotechnology sector is heating up as investors look for the next wave of investment opportunities amid waning resources investment.